company? Let’s change
that.
Don't see your company?
Create a company profileBridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
URL Pharma is a pharmaceuticals company specializing in drug research and development services.
ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. ACELYRIN is embedding a corporate culture of Courageous Caring™—placing patients first and embracing the concept that all of us are better than any one of us. ACELYRIN addresses the most basic human needs—to live a productive life free from diseases.
Inform Diagnostics, previously known as Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, GI pathology, hematology/oncology pathology, and urologic pathology. Additionally, Miraca provides health IT consulting services, and has helped hundreds of practices with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. In November 2017, Miraca Life Sciences was acquired by Avista Capital Partners. As a leader in anatomic pathology, Inform Diagnostics combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Inform Diagnostics, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clinician clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company utilizes a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
Betaliq is a biotech company that focuses on the development of ophthalmic beta-blockers.
Next generation traits company improving the yield, nutrition and sustainability of major global crops.
Providing new objective data to help clinicians navigate infants to safer and faster independent oral feeding.
InduPro is bringing life-changing therapies to patients through novel cell-surface platform technologies. We are defining and manipulating protein interactions beyond natural signaling paradigms. InduPro platforms, integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.
At Koniku Inc., we take the view that a biological neuron is a *material*. An intelligent material or component to be utilized in real life products or devices. Clearly, this proposition opens up a unique set of technology challenges, solvable. It simultaneously offers up an unimaginably vast trove of opportunities. Opportunities ranging from pure-play neurotech, *living devices* to advanced brain-machine interfaces. Koniku is the worlds first corporation of its kind. We are the leading brand in neurotechnology devices. Our goal is to harness the "raw" biological basis of intelligence. Our maxim is: “Bio is Tech™”. We are convinced that “any sufficiently advanced technology is indistinguishable from nature.
Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them. Cellarity is using its platform to design medicines targeting the full cellular and molecular complexity of disease, enabling a quantum leap in the success rate and speed of drug discovery.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
BioAi Health is a leading provider of cutting-edge technologies and services, offering scalable solutions for companies of all sizes. Our platform technology integrates complex data sets from translational studies and clinical trials. We have the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy & drug resistance Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D
BioSurplus is a leading provider of pre-owned laboratory instruments and equipment management services.
Guardion Health Sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe.
Gusto Global focuses on restoring key functionalities of a healthy microbiome.
BioBlocks is a medicinal research organization that provides medicinal chemistry services and products to pharmaceutical customers.
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is unified in a common purpose: creating advanced technology and other trusted solutions to solve the world’s water challenges. We are committed to creating an organization of inclusion and diversity, where everyone feels involved, respected, valued and connected, and where everyone is free to bring their authentic selves and ideas. If you are excited and passionate about helping us #letssolvewater, we want to hear from you!
Sumitovant is a global biopharma company with offices in New York and London. It is the parent company of five biopharmaceutical companies: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. • Sumitovant’s Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharma’s most critical questions. With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market. Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.